Only in Titles

Search results for: Anti elisa rec

paperclip

#38704817   2024/05/05 To Up

Assessment of glial fibrillary acidic protein and anti-glial fibrillary acidic protein autoantibody concentrations and necrotising meningoencephalitis risk genotype in dogs with pug dog myelopathy.

Pugs commonly present with thoracolumbar myelopathy, also known as pug dog myelopathy (PDM), which is clinically characterised by progressive signs involving the pelvic limbs, no apparent signs of pain and, often, incontinence. In addition to meningeal fibrosis and focal spinal cord destruction, histopathology has confirmed lymphohistiocytic infiltrates in the central nervous system (CNS) in a considerable number of pugs with PDM. Lymphohistiocytic CNS inflammation also characterises necrotising meningoencephalitis (NME) in pugs. This study aimed to investigate the potential contribution of an immunological aetiology to the development of PDM.
Cecilia Rohdin, Ingrid Ljungvall, Karin Hultin Jäderlund, Anna Svensson, Kerstin Lindblad-Toh, Jens Häggström

1210 related Products with: Assessment of glial fibrillary acidic protein and anti-glial fibrillary acidic protein autoantibody concentrations and necrotising meningoencephalitis risk genotype in dogs with pug dog myelopathy.

100 25 ml 6 ml 2 ml 1000 TESTS/0.65ml100.00 ug100ug Lyophilized100ug Lyophilized100ug Lyophilized10100ug Lyophilized100

Related Pathways

paperclip

#38008819   2023/11/26 To Up

Neutralizing tumor-related inflammation and reprogramming of cancer-associated fibroblasts by Curcumin in breast cancer therapy.

Tumor-associated inflammation plays a vital role in cancer progression. Among the various stromal cells, cancer-associated fibroblasts are promising targets for cancer therapy. Several reports have indicated potent anti-inflammatory effects attributed to Curcumin. This study aimed to investigate whether inhibiting the inflammatory function of cancer-associated fibroblasts (CAFs) with Curcumin can restore anticancer immune responses. CAFs were isolated from breast cancer tissues, treated with Curcumin, and co-cultured with patients' PBMCs to evaluate gene expression and cytokine production alterations. Blood and breast tumor tissue samples were obtained from 12 breast cancer patients with stage II/III invasive ductal carcinoma. Fibroblast Activation Protein (FAP) + CAFs were extracted from tumor tissue, treated with 10 μM Curcumin, and co-cultured with corresponding PBMCs. The expression of smooth muscle actin-alpha (α-SMA), Cyclooxygenase-2(COX-2), production of PGE2, and immune cell cytokines were evaluated using Real-Time PCR and ELISA, respectively. Analyzes showed that treatment with Curcumin decreased the expression of genes α-SMA and COX-2 and the production of PGE2 in CAFs. In PBMCs co-cultured with Curcumin-treated CAFs, the expression of FoxP3 decreased along with the production of TGF-β, IL-10, and IL-4. An increase in IFN-γ production was observed that followed by increased T-bet expression. According to our results, Curcumin could reprogram the pro-tumor phenotype of CAFs and increase the anti-tumor phenotype in PBMCs. Thus, CAFs, as a component of the tumor microenvironment, are a suitable target for combination immunotherapies of breast cancer.
Elnaz Jalilian, Firoozeh Abolhasani-Zadeh, Ali Afgar, Arash Samoudi, Hamid Zeinalynezhad, Ladan Langroudi

2132 related Products with: Neutralizing tumor-related inflammation and reprogramming of cancer-associated fibroblasts by Curcumin in breast cancer therapy.



Related Pathways

paperclip

#37103583   2023/04/27 To Up

The quantity and quality of anti-SARS-CoV-2 antibodies show contrariwise association with COVID-19 severity: lessons learned from IgG avidity.

Gaining more appreciation on the protective/damaging aspects of anti-SARS-CoV-2 immunity associated with disease severity is of great importance. This study aimed to evaluate the avidity of serum IgG antibodies against SARS-CoV-2 spike (S) and nucleocapsid (N) in hospitalized symptomatic COVID-19 patients and asymptomatic RT-PCR-confirmed SARS-CoV-2 carriers as well as to compare antibody avidities with respect to vaccination status, vaccination dose and reinfection status. Serum levels of anti-S and anti-N IgG were determined using specific ELISA kits. Antibody avidity was determined by urea dissociation assay and expressed as avidity index (AI) value. Despite higher IgG levels in the symptomatic group, AI values of both anti-S and anti-N IgG were significantly lower in this group compared to asymptomatic individuals. In both groups, anti-S AI values were elevated in one-dose and two-dose vaccinees versus unvaccinated subjects, although significant differences were only detected in the symptomatic group. However, anti-N avidity showed no significant difference between the vaccinated and unvaccinated subgroups. Almost all vaccinated patients of different subgroups (based on vaccine type) had higher anti-S IgG avidity, while the statistical significance was detected only between those receiving Sinopharm compared to the unvaccinated subgroup. Also, statistically significant differences in antibody AIs were only found between primarily infected individuals of the two groups. Our findings indicate a key role for anti-SARS-CoV-2 IgG avidity in protection from symptomatic COVID-19 and calls for the incorporation of antibody avidity measurement into the current diagnostic tests to predict effective immunity toward SARS-CoV-2 infection or even for prognostic purposes.
Mehrdad Hajilooi, Fariba Keramat, Akram Moazenian, Mohsen Rastegari-Pouyani, Ghasem Solgi

2708 related Products with: The quantity and quality of anti-SARS-CoV-2 antibodies show contrariwise association with COVID-19 severity: lessons learned from IgG avidity.

0.1 ml100 ul1 ml0.1 mg1 mg0.1 mg250 ug0.5 mg100 ug/vial100 ul100 μg0.2 mg

Related Pathways

paperclip

#34841388   2021/11/20 To Up

Long-term analysis of antibodies elicited by SPUTNIK V: A prospective cohort study in Tucumán, Argentina.

Gam-COVID-Vac (SPUTNIK V) has been granted emergency use authorization in 70 nations and has been administered to millions worldwide. However, there are very few peer-reviewed studies describing its effects. Independent reports regarding safety and effectiveness could accelerate the final approval by the WHO. We aimed to study the long-term humoral immune response in naïve and previously infected volunteers who received SPUTNIK V.
Rossana Elena Chahla, Rodrigo Hernán Tomas-Grau, Silvia Inés Cazorla, Diego Ploper, Esteban Vera Pingitore, Mónica Aguilar López, Patricia Aznar, María Elena Alcorta, Eva María Del Mar Vélez, Agustín Stagnetto, César Luís Ávila, Carolina Maldonado-Galdeano, Sergio Benjamín Socias, Dar Heinze, Silvia Adriana Navarro, Conrado Juan Llapur, Dardo Costa, Isolina Flores, Alexis Edelstein, Shreyas Kowdle, Claudia Perandones, Benhur Lee, Gabriela Apfelbaum, Raúl Mostoslavsky, Gustavo Mostoslavsky, Gabriela Perdigón, Rosana Nieves Chehín

2967 related Products with: Long-term analysis of antibodies elicited by SPUTNIK V: A prospective cohort study in Tucumán, Argentina.

100 μg100 μg100.00 ug100 μg100 μg100 μg100 μg100 μg100 μg100 μg100 μg100 μg

Related Pathways

paperclip

#34761559   2021/11/21 To Up

Development of a microplate duplex immunoassay to simplify detection of growth hormone doping: Proof of concept.

The World Anti-Doping Agency (WADA) prohibits athletes from using recombinant growth hormone (GH). The validated method used in antidoping laboratories for the direct detection of exogenous GH in serum requires two immunoluminometric assays (ILMAs): The first mainly measures the concentration of the full-length (22 kDa) form of GH (recGH), and the second measures concentrations of multiple GH fragments produced by the pituitary gland (22 kDa, 20 kDa and other forms) (pitGH). The tube-by-tube analysis is laborious. A recent development opened new possibilities to simplify the detection of recGH in serum: multiplexed immunoassays that detect multiple targets in a single well of a 96-well plate using an ELISA-like procedure with high sensitivity. Our aim was to evaluate this technology by developing a customized assay for GH detection. One pair of antibodies with specificities similar to those of the recGH assay and one pair of antibodies compatible with pitGH detection were selected for a single duplex assay. Forty-eight serum samples (negative athlete samples and positive samples following GH administration) were analyzed using the two methods. The microplate duplex assay discriminated between the negative athlete samples and the positive controls, although the rec/pit ratios from the duplex assay were lower than those obtained with the ILMAs. This new assay would offer a modern alternative to ILMAs, with fewer analytical steps and a smaller sample volume. However, an adaptation of the decision limits seems mandatory.
Alexandre Marchand, Daisy Roy, Sarah A Monsheimer, Jennifer Lewis, Magnus Ericsson

1719 related Products with: Development of a microplate duplex immunoassay to simplify detection of growth hormone doping: Proof of concept.

100.00 ug1 mg1 mg 5 G500ul100.00 ug1 mg1 mg100

Related Pathways

paperclip

#34683412   2021/10/03 To Up

Case-Control Study to Assess the Association between Epilepsy and Infection/Exposure.

Although causes and etiology of epilepsy are mostly obscure, some zoonotic parasites, such as species, have been proposed as a risk factor for this disease. Here, we conducted an age-matched case-control study to evaluate whether there is an association between epilepsy and the presence of serum antibodies to in incident cases. We included 94 idiopathic epileptic patients as cases, and-from the same geographical region-88 people with no own history of epilepsy or neurological disease as control subjects. Epilepsy was confirmed by a physician using the International League Against Epilepsy (ILAE) definition. All participants were screened for the anti- IgG serum antibody by enzyme-linked immunosorbent assay (ELISA). Univariate and mutltivariate statistical analyses were applied to calculate the crude and adjusted odds ratios (OR) and 95% confidence intervals (CIs). Anti- serum antibody was detected in 37 epileptic patients and in 23 control subjects, giving respective seroprevalences of 39.3% (95% CI, 29.4-49.9%) and 26.1% (95% CI, 17.3-36.5%), respectively. Adjusted multivariate logistic regression analysis estimated an OR of 2.38 (95% CI, 1.25-4.63), indicating a significant association between epilepsy and seropositivity. There was also a significant association between seropositivity to and partial (OR, 2.60; 95% CI, 1.14-6.04) or generalized (OR, 2.17; 95% CI, 1.09-4.40%) seizures. Findings from the present study of incident epileptic cases support previous studies proposing that infection/exposure is a risk factor for epilepsy. However, further well-designed population-based surveys and mechanistic/experimental studies in animal models are required to better understand the reason(s) for this association.
Ali Alizadeh Khatir, Mahdi Sepidarkish, Mohammad Reza Rajabalizadeh, Solmaz Alizadeh Moghaddam, Saeed Aghapour, Saeed Mehravar, Peter J Hotez, Robin B Gasser, Ali Rostami

2527 related Products with: Case-Control Study to Assess the Association between Epilepsy and Infection/Exposure.

1,000 Pieces/case500 MG2 modulesOne 96-Well Strip Micropl

Related Pathways

paperclip

#34216156   2021/07/06 To Up

Assessment of serological assays for identifying high titer convalescent plasma.

The COVID-19 pandemic has been accompanied by the largest mobilization of therapeutic convalescent plasma (CCP) in over a century. Initial identification of high titer units was based on dose-response data using the Ortho VITROS IgG assay. The proliferation of severe acute respiratory syndrome coronavirus 2 serological assays and non-uniform application has led to uncertainty about their interrelationships. The purpose of this study was to establish correlations and analogous cutoffs between multiple serological assays.
Christopher W Farnsworth, James B Case, Karl Hock, Rita E Chen, Jane A O'Halloran, Rachel Presti, Charles W Goss, Adriana M Rauseo, Ali Ellebedy, Elitza S Theel, Michael S Diamond, Jeffrey P Henderson

2061 related Products with: Assessment of serological assays for identifying high titer convalescent plasma.

50 assays1 mg100 assays1ml1ml96T10000 assays0.1ml0.1ml1mg1000 assays1mg

Related Pathways

paperclip

#33874981   2021/04/19 To Up

A randomised, double-blind, placebo-controlled, pilot trial of intravenous plasma purified alpha-1 antitrypsin for SARS-CoV-2-induced Acute Respiratory Distress Syndrome: a structured summary of a study protocol for a randomised, controlled trial.

The primary objective is to demonstrate that, in patients with PCR-confirmed SARS-CoV-2 resulting in Acute Respiratory Distress Syndrome (ARDS), administration of 120mg/kg of body weight of intravenous Prolastin®(plasma-purified alpha-1 antitrypsin) reduces circulating plasma levels of interleukin-6 (IL-6). Secondary objectives are to determine the effects of intravenous Prolastin® on important clinical outcomes including the incidence of adverse events (AEs) and serious adverse events (SAEs).
Natalie L McEvoy, Jennifer L Clarke, Oliver J Mc Elvaney, Oisin F Mc Elvaney, Fiona Boland, Deirdre Hyland, Pierce Geoghegan, Karen Donnelly, Oisin Friel, Ailbhe Cullen, Ann M Collins, Daniel Fraughen, Ignacio Martin-Loeches, Martina Hennessy, John G Laffey, Noel G Mc Elvaney, Gerard F Curley

2675 related Products with: A randomised, double-blind, placebo-controlled, pilot trial of intravenous plasma purified alpha-1 antitrypsin for SARS-CoV-2-induced Acute Respiratory Distress Syndrome: a structured summary of a study protocol for a randomised, controlled trial.

500 G 1 G1,000 tests0.25 mg100ug0.2 mg25 g25 µg20 ug5 g100μg0.1 ml

Related Pathways

paperclip

#33801107   2021/03/21 To Up

Functional Autoreactive Anti-β2 Adrenergic Antibodies May Contribute to Insulin Resistance Profile in Patients with Chronic Chagas Disease.

Potential activation of β2 adrenergic receptors (β2AR) by specific autoreactive antibodies (Abs) that arise during the host reaction to , could contribute to the elevated prevalence of metabolic disturbances described in patients with chronic Chagas disease (CCD). This study aimed to determine the prevalence of anti-β2AR Abs in patients with CCD, as well as the correlation of these Abs with the presence of glucose and lipid metabolism disturbances, in order to explore their association with an insulin resistance profile. Additionally, we tested the functional effects of anti-β2AR Abs employing an in vitro bioassay with neuroendocrine cells expressing β2AR. A clinical and metabolic evaluation including an OGTT was performed in 80 CCD patients and 40 controls. Anti-β2AR Abs were measured by an in-house-developed ELISA, and the β2 adrenergic activity of affinity-purified IgG fractions from patient' sera were assayed in CRE-Luc and POMCLuc transfected AtT-20 cells. A higher proportion of dysglycemia (72.5% vs. 37.5%; = 0.001) was observed in the CCD group, accompanied by increased HOMA2-IR ( = 0.019), especially in subjects with Abs (+). Anti-β2AR Abs reactivity (7.01 (2.39-20.5); = 0.0004) and age >50 years (3.83 (1.30-11.25); = 0.014) resulted as relevant for IR prediction (AUC: 0.786). Concordantly, Abs (+) CCD patients showed elevated metabolic risk scores and an increased prevalence of atherogenic dyslipidemia ( = 0.040), as compared to Abs (-) patients and controls. On functional bioassays, Abs exerted specific and dose-dependent β2-agonist effects. Our findings suggest that anti-β2AR Abs may induce the activation of β2AR in other tissues besides the heart; furthermore, we show that in patients with CCD these Abs are associated with an insulin resistance profile and atherogenic dyslipidemia, providing biological plausibility to the hypothesis that adrenergic activation by anti-β2AR Abs could contribute to the pathogenesis of metabolic disturbances described in CCD patients, increasing their cardiovascular risk.
Luz María Rodeles, Miguel Hernán Vicco, Álvaro Siano, Leonardo Andrés Fuchs, Luz María Peverengo, Silvia Sanchez Puch, Cora Beatriz Cymeryng, Iván Sergio Marcipar, Pablo Arias

1399 related Products with: Functional Autoreactive Anti-β2 Adrenergic Antibodies May Contribute to Insulin Resistance Profile in Patients with Chronic Chagas Disease.

100.00 ug100.00 ug 50 UG100 μg100 100.00 ug100.00 ug1 mg100.00 ug1 mg100.00 ug100 μg

Related Pathways

paperclip

#32865318   2020/09/24 To Up

Isorhamnetin attenuates TNF-α-induced inflammation, proliferation, and migration in human bronchial epithelial cells via MAPK and NF-κB pathways.

Isorhamnetin has distinct anti-inflammatory activity and inhibits cell proliferation and migration. These effects are also involved in the pathogenesis of asthma. However, the effect of isorhamnetin on bronchial epithelial cells in patients with asthma has not been examined. Cells of human bronchial epithelial cell line BEAS-2B were cultured with isorhamnetin and tumor necrosis factor (TNF)-α. The effects of isorhamnetin on BEAS-2B cell viability were assessed using CCK8 assay. The EdU (5-ethynyl-2'-deoxyuridine) cell proliferation assay was performed to assess cell proliferation. BEAS-2B cell migration was measured using Transwell and wound healing assays. Real-time PCR and enzyme-linked immunosorbent assay were conducted to measure the expression of pro-inflammatory cytokines. Protein expression levels were determined by western blotting. Immunofluorescence was used to detect nuclear translocation of nuclear factor kappa B (NF-κB). We found that isorhamnetin at 20 and 40 μM reduced the proliferation of BEAS-2B cells induced by TNF-α. Isorhamnetin significantly decreased the expression of interleukin (IL)-1β, IL-6, IL-8, and C-X-C motif chemokine ligand 10 in BEAS-2B cells induced by TNF-α. Additionally, 10 μM isorhamnetin effectively reduced cell migration induced by TNF-α. Treatment with isorhamnetin inhibited the phosphorylation of mitogen-activated protein kinase (MAPK) and NF-κB pathways induced by TNF-α. In summary, isorhamnetin inhibited the inflammation, proliferation, and migration of BEAS-2B cells by regulating the MAPK and NF-κB signaling pathways and is a drug candidate for asthma.
Xiaojie Ren, Longyin Han, Yongxing Li, Huanyi Zhao, Ziyin Zhang, Yuerong Zhuang, Ming Zhong, Qiang Wang, Wuhua Ma, Yong Wang

2051 related Products with: Isorhamnetin attenuates TNF-α-induced inflammation, proliferation, and migration in human bronchial epithelial cells via MAPK and NF-κB pathways.

50 ul1.00 flask4 Membranes/Box16 Arrays/Slide100 ug/vial4 Sample Kit0.1 mg8 Sample Kit1.00 flask1 mg100 ul4 Membranes/Box

Related Pathways